secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2025-03-06T23:59:59+00:00
Accession:  0001193125-25-048423
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre dismisses PwC as auditor, appoints KPMG; discloses material weakness in controls
--------------------------------------------------------------------------------

- PwC dismissed as auditor effective Feb 28, 2025; KPMG appointed as new independent auditor for FY2025.
- No disagreements with PwC on accounting principles; material weakness identified as of Dec 31, 2024 in controls over EPS calculation for convertible preferred stock.
- Material weakness led to restatement of FY2023 consolidated financial statements.
- PwC's reports for FY2024 and FY2023 were unqualified.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312525048423/0001193125-25-048423-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312525048423/d861533d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-048423

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer